{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:41:05Z","timestamp":1769881265205,"version":"3.49.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The management of Peyronie's disease (PD) is a challenge for the clinician. Despite the lack of etiologic therapy, different nonsurgical approaches have often been empirically proposed. The most used treatment is based on nutraceutical drugs with antioxidant activity, although such an intervention remains controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We reviewed the evidence from the randomized controlled trials included in the recommendations of the American Urological Association (AUA), Canadian Urological Association (CUA), European Association of Urology, and International Society for Sexual Medicine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched PubMed, Scopus, Web of Science, and Cochrane Library for randomized controlled trials, reviews, and guidelines on nutraceutical interventions for PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our analysis provides detailed information on potential interventions, underlying the inconsistent evidence. Acetyl esters of carnitine, although not recommended by any of the available guidelines, showed potential benefit in some selected studies. Omega-3 fatty acids are not recommended due to withdrawn study evidence. The CUA and AUA were the only societies to consider the use of coenzyme Q10. While the CUA suggested that it might be offered as a treatment option, the AUA refrained from taking a definitive stance due to insufficient evidence. Similarly, conflicting recommendations have been produced on potassium para-aminobenzoate. While the CUA considers potassium para-aminobenzoate potentially useful in slowing PD progression, the AUA deems the evidence insufficient. Conversely, both the International Society for Sexual Medicine and European Association of Urology do not recommend its use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This critical comparative analysis of the most recent guidelines produced by the leading scientific societies highlights some inconsistencies in the recommendations on nutraceutical intervention for PD, even within a background of overall ineffectiveness of this treatment approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sxmrev\/qeae038","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T10:16:48Z","timestamp":1716977808000},"page":"747-753","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of evidence on nutraceutical interventions for Peyronie\u2019s disease: a guideline-based critical review"],"prefix":"10.1093","volume":"12","author":[{"given":"Daniele","family":"Tienforti","sequence":"first","affiliation":[{"name":"Andrology Unit , Department of Clinical Medicine, Life, Health and Environmental Sciences, , 67100 Coppito, L'Aquila ,","place":["Italy"]},{"name":"University of L'Aquila , Department of Clinical Medicine, Life, Health and Environmental Sciences, , 67100 Coppito, L'Aquila ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malvina","family":"Hoxha","sequence":"additional","affiliation":[{"name":"Department for Chemical-Toxicological and Pharmacological Evaluation of Drugs , Faculty of Pharmacy, , 1000 Tirana ,","place":["Albania"]},{"name":"Catholic University Our Lady of Good Counsel , Faculty of Pharmacy, , 1000 Tirana ,","place":["Albania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso Boris","family":"Di Pasquale","sequence":"additional","affiliation":[{"name":"Urology Unit , Department of Urology, , 67100 Coppito, L\u2019Aquila,","place":["Italy"]},{"name":"S. Salvatore Hospital , Department of Urology, , 67100 Coppito, L\u2019Aquila,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicio","family":"Rizza","sequence":"additional","affiliation":[{"name":"General Surgery Unit, Surgical Department, S.S. Maria Dello Splendore Hospital , 64021 Giulianova (TE) ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arcangelo","family":"Barbonetti","sequence":"additional","affiliation":[{"name":"Andrology Unit , Department of Clinical Medicine, Life, Health and Environmental Sciences, , 67100 Coppito, L'Aquila ,","place":["Italy"]},{"name":"University of L'Aquila , Department of Clinical Medicine, Life, Health and Environmental Sciences, , 67100 Coppito, L'Aquila ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"1","key":"2024100104310682100_ref1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J Urol"},{"issue":"4","key":"2024100104310682100_ref2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0022-5347(01)64222-8","article-title":"Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction","volume":"158","author":"Jarow","year":"1997","journal-title":"J Urol"},{"issue":"3","key":"2024100104310682100_ref3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.aju.2013.06.006","article-title":"The pathophysiology of Peyronie's disease","volume":"11","author":"El-Sakka","year":"2013","journal-title":"Arab J Urol"},{"key":"2024100104310682100_ref4","doi-asserted-by":"crossref","first-page":"4653512","DOI":"10.1155\/2017\/4653512","article-title":"Recent pathophysiological aspects of Peyronie's disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review","volume":"2017","author":"Paulis","year":"2017","journal-title":"Adv Urol"},{"issue":"5 Suppl","key":"2024100104310682100_ref5","first-page":"450","article-title":"Role of transforming growth factor beta in the pathophysiology of chronic inflammation","volume":"64","author":"Wahl","year":"1993","journal-title":"J Periodontol"},{"issue":"1","key":"2024100104310682100_ref6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00345-008-0320-x","article-title":"Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease","volume":"27","author":"Szardening-Kirchner","year":"2009","journal-title":"World J Urol"},{"issue":"24","key":"2024100104310682100_ref7","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.3390\/ijms232415969","article-title":"Role of oxidative stress in Peyronie's disease: biochemical evidence and experiences of treatment with antioxidants","volume":"23","author":"Paulis","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2024100104310682100_ref8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","article-title":"Role of oxidative stress and antioxidants in Peyronie's disease","volume":"14","author":"Sikka","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024100104310682100_ref9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cotox.2017.11.002","article-title":"NF-\u03baB in oxidative stress","volume":"7","author":"Lingappan","year":"2018","journal-title":"Curr Opin Toxicol"},{"issue":"5","key":"2024100104310682100_ref10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ijir.3900872","article-title":"Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease","volume":"14","author":"Bivalacqua","year":"2002","journal-title":"Int J Impot Res"},{"issue":"3","key":"2024100104310682100_ref11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2164\/jandrol.05136","article-title":"Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction","volume":"27","author":"Agarwal","year":"2006","journal-title":"J Androl"},{"issue":"7","key":"2024100104310682100_ref12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"2024100104310682100_ref13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/JIR.S275595","article-title":"Reactive oxygen species: drivers of physiological and pathological processes","volume":"13","author":"Checa","year":"2020","journal-title":"J Inflamm Res"},{"issue":"4","key":"2024100104310682100_ref14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/biomedicines9040432","article-title":"Anatomy, pathophysiology, molecular mechanisms, and clinical management of erectile dysfunction in patients affected by coronary artery disease: a review","volume":"9","author":"Sangiorgi","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"2024100104310682100_ref15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5534\/wjmh.200065","article-title":"The natural history of Peyronie's disease","volume":"39","author":"Di Maida","year":"2021","journal-title":"World J Mens Health"},{"issue":"3","key":"2024100104310682100_ref16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JU.0000000000001426","article-title":"Mental disorders in Peyronie's disease: a Swedish cohort study of 3.5 million men","volume":"205","author":"Kuja-Halkola","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"2024100104310682100_ref17","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0022-5347(17)39746-X","article-title":"The natural history of Peyronie's disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J Urol"},{"issue":"3","key":"2024100104310682100_ref18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie's disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"issue":"1","key":"2024100104310682100_ref19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bju.12346","article-title":"Deformity stabilization and improvement in men with untreated Peyronie's disease","volume":"113","author":"Berookhim","year":"2014","journal-title":"BJU Int"},{"issue":"1","key":"2024100104310682100_ref20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"issue":"7","key":"2024100104310682100_ref21","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/andr.13414","article-title":"Real-world practice in Peyronie's disease management: results from a national survey of urologists","volume":"11","author":"Brant","year":"2023","journal-title":"Andrology"},{"issue":"3","key":"2024100104310682100_ref22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie's disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"2024100104310682100_ref23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J Sex Med"},{"issue":"5","key":"2024100104310682100_ref24","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.5489\/cuaj.5255","article-title":"2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature","volume":"12","author":"Bella","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"2024100104310682100_ref25","volume-title":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023","author":"Salonia","year":"2023"},{"issue":"4_Part_2","key":"2024100104310682100_ref26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1743-6109.2007.00537.x","article-title":"A survey of primary-care physicians and urologists regarding Peyronie's disease","volume":"4","author":"LaRochelle","year":"2007","journal-title":"J Sex Med"},{"issue":"2","key":"2024100104310682100_ref27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/andr.292","article-title":"Peyronie's disease: urologist's knowledge base and practice patterns","volume":"3","author":"Sullivan","year":"2015","journal-title":"Andrology"},{"issue":"17","key":"2024100104310682100_ref28","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.3390\/molecules26175385","article-title":"Synergistic action of membrane-bound and water-soluble antioxidants in neuroprotection","volume":"26","author":"Polutchko","year":"2021","journal-title":"Molecules"},{"issue":"9","key":"2024100104310682100_ref29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/00365520903114912","article-title":"Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice","volume":"44","author":"Nan","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"2024100104310682100_ref30","first-page":"41","article-title":"Controlled clinical trial of vitamin E in Peyronie\u2019s disease","volume":"9","author":"Pryor","year":"1983","journal-title":"Prog Reprod Biol Med"},{"issue":"6","key":"2024100104310682100_ref31","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","article-title":"Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease","volume":"91","author":"Prieto Castro","year":"2003","journal-title":"BJU Int"},{"issue":"1","key":"2024100104310682100_ref32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases","volume":"1","author":"Paulis","year":"2013","journal-title":"Andrology."},{"issue":"4","key":"2024100104310682100_ref33","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"2024100104310682100_ref34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871528111312010009","article-title":"Peironimev-plus\u00ae in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). Results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1","key":"2024100104310682100_ref35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"BJU Int"},{"issue":"9","key":"2024100104310682100_ref36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","article-title":"Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease","volume":"89","author":"Cavallini","year":"2002","journal-title":"BJU Int"},{"issue":"6","key":"2024100104310682100_ref37","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1743-6109.2009.01235.x","article-title":"RETRACTED: efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study","volume":"6","author":"Safarinejad","year":"2009","journal-title":"J Sex Med"},{"key":"2024100104310682100_ref38","first-page":"61","article-title":"A multicentre double-blind controlled clinical trial of potassium para-amino-benzoate (POTABA1) in Peyronie\u2019s disease","volume":"9","author":"Shah","year":"1983","journal-title":"Progr Reprod Biol Med J"},{"issue":"4","key":"2024100104310682100_ref39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"issue":"5","key":"2024100104310682100_ref40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Int J Impot Res"},{"key":"2024100104310682100_ref41","article-title":"Expression of concern: comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study","author":"Safarinejad","year":"10, 2023","journal-title":"J Urol"},{"issue":"4","key":"2024100104310682100_ref42","first-page":"521","article-title":"The mitochondrial carnitine acyl-carnitine carrier (SLC25A20): molecular mechanisms of transport, role in redox sensing and interaction with drugs","volume":"11","author":"Tonazzi","year":"2021","journal-title":"Biomol Ther"},{"issue":"6","key":"2024100104310682100_ref43","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/0002-8703(92)90850-U","article-title":"Carnitine and its acyl esters as secondary antioxidants?","volume":"123","author":"Arduini","year":"1992","journal-title":"Am Heart J"},{"issue":"5","key":"2024100104310682100_ref44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0955-2863(00)00151-0","article-title":"Protective role of L-carnitine on liver and heart lipid peroxidation in atherosclerotic rats","volume":"12","author":"Dayanandan","year":"2001","journal-title":"J Nutr Biochem"},{"issue":"6","key":"2024100104310682100_ref45","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie's disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J Urol"},{"key":"2024100104310682100_ref46","article-title":"A spectrophotometric method for determining the amount of folic acid in fortified salt","volume":"2","author":"Modupe","year":"2020","journal-title":"J Agric Food Res"},{"issue":"6","key":"2024100104310682100_ref47","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","article-title":"Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba)","volume":"81","author":"CJ","year":"1959","journal-title":"J Urol"},{"issue":"1","key":"2024100104310682100_ref48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2340\/00015555721518","article-title":"A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts","volume":"72","author":"Griffiths","year":"1992","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"2024100104310682100_ref49","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/j.1743-6109.2008.00918.x","article-title":"Acute hepatitis associated with treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba)","volume":"5","author":"Roy","year":"2008","journal-title":"J Sex Med"},{"issue":"4","key":"2024100104310682100_ref50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/antiox6040103","article-title":"Co-enzyme Q10 and n-3 polyunsaturated fatty acid supplementation reverse intermittent hypoxia-induced growth restriction and improved antioxidant profiles in neonatal rats","volume":"6","author":"Beharry","year":"2017","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"2024100104310682100_ref51","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/antiox10050695","article-title":"Pathophysiology of mitochondrial dysfunction in human spermatozoa: focus on energetic metabolism, oxidative stress and apoptosis","volume":"10","author":"Castellini","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"2024100104310682100_ref52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.taap.2009.07.030","article-title":"Inhibition of liver fibrosis by solubilized coenzyme Q10: role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression","volume":"240","author":"Choi","year":"2009","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/12\/4\/747\/59335157\/qeae038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/12\/4\/747\/59335157\/qeae038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T04:31:23Z","timestamp":1727757083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smr\/article\/12\/4\/747\/7683889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,28]]},"published-print":{"date-parts":[[2024,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/sxmrev\/qeae038","relation":{},"ISSN":["2050-0513","2050-0521"],"issn-type":[{"value":"2050-0513","type":"print"},{"value":"2050-0521","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,28]]}}}